Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EB103 |
Synonyms | |
Therapy Description |
Limited information is currently available on EB103, a putative CD19-targeted T-cell therapy (Aug 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EB103 | EB 103|EB-103 | CD19 Immune Cell Therapy 62 | Limited information is currently available on EB103, a putative CD19-targeted T-cell therapy (Aug 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06343311 | Phase Ib/II | EB103 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1) | Recruiting | USA | 0 |